Induction and maintenance of clinical remission by interferon-β in patients with steroid-refractory active ulcerative colitis - An open long-term pilot trial

Alimentary Pharmacology and Therapeutics

Volumn 16, Issue 7, 2002, Pages 1233-1239

  Musch, E ^a,d   Andus, T ^b   Malek, M ^c  

^a Marienhospital Bottrop ^*  (Germany)

^b Klinikum Stuttgart Krankenhaus Bad Cannstatt   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d Marien Hospital Bottrop gGmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; RECOMBINANT GAMMA INTERFERON; GLUCOCORTICOID; IMMUNOLOGICAL ADJUVANT; RECOMBINANT INTERFERON;

ADOLESCENT; ADULT; AGED; ALOPECIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLU LIKE SYNDROME; HUMAN; IMMUNOTHERAPY; LONG TERM CARE; MALE; PRIORITY JOURNAL; REMISSION; ULCERATIVE COLITIS; DRUG RESISTANCE; MIDDLE AGED; PILOT STUDY; PROSPECTIVE STUDY; RECURRENT DISEASE; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; COLITIS, ULCERATIVE; DRUG RESISTANCE; FEMALE; GLUCOCORTICOIDS, SYNTHETIC; HUMAN; INTERFERON TYPE I, RECOMBINANT; INTERFERON-BETA; MALE; MIDDLE AGE; PILOT PROJECTS; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; SUPPORT, NON-U.S. GOV'T; TREATMENT OUTCOME; GLUCOCORTICOIDS; HUMANS; MIDDLE AGED;

EID: 0036024194     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2002.01264.x     Document Type: Article

References (33)

1. Sulfasalazine revisited: A meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis
2. Metaanalysis of the effectiveness of current drug therapy of ulcerative colitis
3. Ciclosporin in severe ulcerative colitis refractory to steroid therapy
4. Factors affecting colectomy rate in ulcerative colitis: An epidemiologic study
5. Morbidity of subtotal colectomy in patients with severe ulcerative colitis unresponsive to cyclosporin
6. Etiology and pathophysiology of inflammatory bowel disease - Environmental factors
7. Inflammatory bowel disease: Etiology and pathogenesis
8. Ulcerative colitis
9. Novel genetic association between ulcerative colitis and the antiinflammatory cytokine interleukin-1 receptor antagonist
10. Imbalance of the interleukin 1 system in colonic mucosa - Association with intestinal inflammation and interleukin-1 receptor antagonist genotype 2
11. A short-term study of chronic monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's Disease cA2 Study Group
12. Treatment of ulcerative colitis with an engineered human anti-TNFα antibody CHP571
13. Treatment of Crohn's disease with interferon. A preliminary clinical trial
14. Interferon-α2a (Roferon) treatment of inflammatory bowel disease in children and adolescents. Inflammatory bowel disease and morbus Hirschsprung
15. Tolerability of interferon-α2b, a possible new treatment of active Crohn's disease
16. Alpha-Interferon therapy in Crohn's disease: Initial clinical results
17. Interferon treatment in mild to moderate active Crohn's disease: Preliminary results of an open label pilot study
18. Prospective evaluation of interferon α in treatment of chronic active Crohn's disease
19. Alpha-interferon was not effective treatment of patients with ulcerative colitis
20. Induction of remission by interferon-a in patients with chronic active ulcerative colitis
21. Multiple sclerosis
22. Mechanisms of action of interferon-β in multiple sclerosis
23. Interferon β in multiple sclerosis
24. Interferon β induces interleukin 10 expression: Relevance to multiple sclerosis
25. Induction of IL-1 receptor antagonist by interferon β: Implication for the treatment of multiple sclerosis
26. Immunmodulatory effects of interferon-β-1a in multiple sclerosis
27. Release of arachidonic acid metabolite by human monocytes or lymphocytes: Effect of treatment with interferon on stimulation by phorbol ester or calicium ionophore
28. Interferon-a enhances the prodution of leukotriene B4 in murine peritoneal macrophages stimulated by opsonized zymosan
29. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomised trial
30. Quantification of the placebo response in ulcerative colitis
31. Cyclosporin for the inflammatory bowel disease: Mechanisms and possible actions
32. Induction of remission by interferon-α in patients with chronic active ulcerative colitis
33. Interferon alpha (IFN α2a) therapy for herpes virus-associated inflammatory bowel disease (ulcerative colitis and Crohn's disease)